Shamburg News · 8-K filed Nov 6, 2026, 4:06 PM EST

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial; Primary Endpoint Moved to Week 48

KARD · Kardigan, Inc.

  • Reg FD disclosure
  • Other event
  • Materiality: high

Kardigan, Inc. announced on November 6, 2026 that it completed enrollment in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, with 156 participants enrolled. The company moved the primary endpoint of aortic valve calcium assessment to Week 48, alongside aortic valve area and cardiac structure and function measures, after amending the protocol under blinded conditions. The press release projects Week 48 topline data in the second half of 2027, and the company will host an investor webcast on November 7, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 7.01, accession 0001193125-26-451836.

Written from the filing by Shamburg Markets. Figures are as reported by the company.